Text Size

Pharmaceutical Care for Asthma Control Improvement (PHARMACI)-Study

This study has been completed.
Sponsor:
Information provided by:
University Ghent
ClinicalTrials.gov Identifier:
NCT00263159
First received: December 6, 2005
Last updated: December 19, 2007
Last verified: December 2007
History of Changes
  Purpose

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients.


Condition Intervention
Asthma
 Procedure: Pharmaceutical care for asthma patients

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Pharmaceutical Care for Asthma Control Improvement

Resource links provided by NLM:

MedlinePlus related topics: Asthma
U.S. FDA Resources

Further study details as provided by University Ghent:

Primary Outcome Measures:
  • The difference between study groups in the change of asthma control from baseline and follow-up visits [ Time Frame: after 1, 3 and 6 months ]

Secondary Outcome Measures:
  • Peak flow [ Time Frame: after 3 and 6 months ]
  • Knowledge of asthma and treatment [ Time Frame: after 6 months ]
  • Asthma quality of life questionnaire (AQLQ) [ Time Frame: after 6 months ]
  • Therapy adherence
  • Inhalation techniques [ Time Frame: after 6 months ]
  • Smoking [ Time Frame: after 6 months ]
  • Asthma exacerbations [ Time Frame: after 6 months ]
  • General Practitioner (GP) visits, emergency room visits and hospitalisations
  • Working days lost and school days lost

Enrollment: 221
Study Start Date: January 2006
Study Completion Date: October 2006
Detailed Description:

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients. Patients will be randomly allocated to the control group (= no input from pharmacist) or intervention group (= with pharmaceutical care at baseline and follow-up visits over 6 months).

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with persistent asthma
  • Asthma treatment for at least 12 months
  • Regular visitors of the participating community pharmacy

Exclusion Criteria:

  • Severe co-morbidity
  • > 10 pack-years smoking history
  • Asthma Control Test score < 15 or =25
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00263159

Locations
Belgium
University Hospital Ghent
Ghent, Belgium, 9000
Sponsors and Collaborators
University Ghent
Investigators
Principal Investigator: Guy Brusselle, MD, PhD University Hospital, Ghent
  More Information

Additional Information:
Website of the University Ghent  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT00263159     History of Changes
Other Study ID Numbers: 2005/320
Study First Received: December 6, 2005
Last Updated: December 19, 2007
Health Authority: Belgium: Institutional Review Board

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
 Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on May 23, 2013